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venesection therapy [3]. They were taken back by the French
Haute Autorité de Santé [4]. Then, all our patients received
the same information about both initial and maintenance
therapy for several decades.
- Delatycki et al. discuss about morbidity aspects. However we
studied mortality and not morbidity. Fortunately a large pro-
portion of patients with breast or colon cancer do not die from
their malignancy. Thus it is not correct to compare mortality
and morbidity data. This is likely also true for cardiovascular
disease.
More importantly, iron stores in the body of patients who
were not venesected because of normal SF at diagnosis were
and remained higher than in those with moderately increased
SF who were early enrolled in a phlebotomy program. Indeed,
maintenance of SF below 50 lg/L results in lower than normal
body iron stores. Therefore, assimilating two sub-groups that
were absolutely not identical with respect to iron burden raises
serious concerns.
For all these reasons we persist to hypothesize that the dis-
crepancy in mortality data between patients with normal SF
and those with moderately increased SF strongly supports a ben-
eﬁcial role of early management of hemochromatosis. However
we agree that, as already stressed in our manuscript, we did
not demonstrate that iron removal per se was responsible for
decreasing mortality. Other factors must be discussed (lifestyle
modiﬁcations, medical follow-up etc.). Nevertheless, the fact that
patients had lower mortality when treated for mild hemochro-
matosis was well shown in this study, regardless of its precise
cause.
Finally, in our view, a randomized study of venesection
therapy in mild hemochromatosis is neither realistic nor ethical.
Moreover, the AASLD guidelines endorsed by Powell et al. do not
suggest to perform such a study and recommend that «. . . C282Y
homozygotes who have an elevated ferritin (but <1000 lg/L)
should proceed to phlebotomy . . .» [5].
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OpenPreservation injury of the distal extrahepatic bile duct of donor
livers is representative for injury of the intrahepatic bile ductsof PBG and vascular plexus correlates strongly with the develop-
ment of NAS after transplantation suggests that insufﬁcient
regeneration of biliary epithelial lining after liver transplanta-
tion, due to destruction of the progenitor cell niche (i.e. the
PBGs) and insufﬁcient blood supply to bile ducts, is a critical
component in the pathogenesis of NAS [1,4]. In our previous
study, as well as two other studies on bile duct histology of
donor livers, biopsies could only be obtained from the distal
end of the donor extrahepatic bile duct [2,3]. It is, however,
unknown whether the degree of injury at this level is represen-
tative for the degree of injury in the rest of the biliary tree,
including intrahepatic bile ducts.
To investigate whether histological injury detected in biopsies
taken from the distal end of a donor liver bile duct isTo the Editor:
We recently published an article in the Journal of Hepatology
describing the histology of biopsies taken from the distal end of
the extrahepatic bile duct of donor livers at the time of
transplantation [1]. This study demonstrated the presence of
severe biliary injury, characterized by loss of the lining biliary
epithelium, mural stroma necrosis, as well as injury of the
peribiliary glands (PBG) and peribiliary vasculature. Injury of
deep PBG and peribiliary vasculature was identiﬁed as signiﬁcant
predictors of later development of non-anastomotic biliary stric-
tures (NAS) after transplantation [1]. Severe injury and loss of the
lining biliary epithelium is almost universally found in over 90%
of donor extrahepatic bile duct biopsies taken at the time of
transplantation [2,3]. The observation that the degree of injuryJournal of Hepatology 2015 vol. 63 j 276–288
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representative for the degree of injury of more proximal and
intrahepatic large bile ducts, we have performed a study in nine
donor livers that were declined for transplantation for various
reasons (Table 1). Livers were collected after informed consent
for research was obtained from donor relatives. All livers were
procured in a standard fashion and preserved by cold ﬂush out
and storage in University of Wisconsin solution. After a median
static cold storage time of 6.7 h biopsies were taken from the dis-
tal end of the extrahepatic bile duct as well as intrahepatic bile
ducts at two different levels of sectoral ducts and segmental
ducts (Fig. 1A). Injury of the bile ducts was assessed using a sys-
tematic histological scoring system as described previously [1,2]
and were compared as matched pairs.
Biliary epithelial loss of >50% of the bile duct lumen was
observed in all different levels of the biliary tree (Fig. 1B). The
degree of mural stroma necrosis was not different among
extrahepatic and intrahepatic bile ducts (Fig. 1B and C). There
was minimal injury of peribiliary vascular plexus (<50% vascular
changes) in 92.5% of all the biopsies and there was no signiﬁcant
difference among extrahepatic and intrahepatic bile ducts
(Fig. 1D and E). No signs of microthrombi were found in the peri-
biliary vascular plexus and only minimal intramural bleeding
(<50% of the bile duct) was observed in 5% of all biopsies. The
degree of injury detected in periluminal PBG as well as in deep
PBG was not signiﬁcantly different among the various levels of
the biliary tree (Fig. 1F–I). Severe injury (>50% epithelial loss)
of the periluminal PBG was found in 40% of the livers, while
severe injury of deep PBG was observed in only 6.6%
(p <0.0001; v2 test).
This is the ﬁrst study describing the degree of histological
injury of donor liver bile ducts at different levels of the biliary
tree, including larger intrahepatic bile ducts. In accordance with
previous studies [2,3], histological examination of bile ducts of
donor livers after static cold preservation revealed signs of exten-
sive injury. The current study adds important new information to
the existing knowledge on biliary preservation injury obtained
from studies describing the degree of injury in distal extrahepatic
bile duct biopsies of donor livers [2,3].
A limitation of this study is that the donor liver grafts used
were declined for transplantation by centers within
Eurotransplant regions. However, the type and degree of bile
duct injury observed at the level of distal extrahepatic bile duct
was similar to that described before in our previous study
including 128 liver grafts that were used for transplantation
[2,3], as well as an experimental study using a porcine donation
after circulatory death model [5]. Moreover, due to the nature of
this study, which included collection of biopsies from larger
intrahepatic bile ducts, there is no possibility to perform such
a study in donor livers that are accepted for transplantation.
Another limitation of this study is the small number of liver
grafts used. Unfortunately, human livers are not available for
research in large numbers.
In conclusion, the degree of histological injury detected at
distal end of extrahepatic bile duct of a donor liver is also rep-
resentative for the degree of injury in the proximal parts of the
biliary tree, including larger intrahepatic bile ducts. This study
indicates that the biopsies taken from the distal end of the
donor extrahepatic bile ducts are a valuable tool in research
focusing on preservation injury of donor bile ducts during liver
transplantation.
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Table 1. Donor characteristics and surgical variables.
Variable Number (%) or median (IQR)
Age (years) 65 (52-68)
Gender (male) 7 (78%)
Body mass Index 26 (23-30)
Cause of death
Cardiovascular 3 (34%)
Trauma 2 (22%)
Post-anoxia 2 (22%)
Brain tumor (benign) 1 (11%)
Subarachnoid hemorrhage 1 (11%)
Type of donor
DCD, Maastricht type III 8 (89%)
DBD 1 (11%)
Reason livers were declined for 
transplantation
DCD+ age >60 years 5 (56%)
DCD+ high body mass index 1 (11%)
DCD+ high serum 
transaminases
2 (22%)
DBD+ adenomatosis hepatis 1 (11%)
Preservation solution
University of Wisconsin solution 9 (100%)
Type of graft
Full size graft 9 (100%)
Donor warm ischemia time in 
DCD* (min)
17 (14-21)
Cold ischemia time (min) 433 (322-560)
⁄Donor warm ischemia was deﬁned from the moment of cardiac arrest after
planned withdrawal of life support until cold ﬂush out. DCD, donation after
circulatory death; DBD, donation after brain death.
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Fig. 1. Histological assessment of bile duct (BD) injury at various levels of the biliary tree of human donor livers. (A) Schematic overview of the different levels at
which biopsies were taken. Light microscopy (hematoxylin & eosin staining) of extrahepatic and intrahepatic bile duct biopsies showed no signiﬁcant differences in the
degree of (B and C) biliary epithelium loss and mural stroma necrosis, (D and E) peribiliary vascular plexus, (F and G) periluminal peribiliary glands (PBG), and (H and I)
deep PBG at the three different levels of the biliary tree. The degree of injury of the various bile duct wall components was assessed using a histological grading system as
described previously (1). ⁄Bile duct lumen; #bile duct wall. Arrows point at blood vessels of the peribiliary vascular plexus. Dotted circles indicate the periluminal PBG and
dashed circle indicate the deep PBG.
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Hepatic encephalopathy treatment and its effect on driving abilities:
A continental divide
To the Editor:
We read with great interest the review article on hepatic
encephalopathy (HE) that, in addition to the recent EASL/AASLD
guidelines, is informative about the spectrum of this disease
[1,2]. We set out to evaluate the practice patterns of clinical HE
experts worldwide (285 ISHEN members and authors of clinical
HE articles in the last 5 years) through a systematic electronic
questionnaire focused on the management and effect on driving
ability in HE. Results are summarized in the Table 1.
Response rate was 35%. Respondents were from 23 different
countries in 4 different continents (Europe: n = 48, Americas
n = 28, Asia: n = 21). Sixty per cent specialized in hepatology and
most had more than 10 years of clinical experience.
Management of overt HE (OHE) is similar between continents
and complies with guidelines, although medical management dif-
fers in some aspects: in the US rifaximin is used as much as lactu-
lose (by 96%) but in Europe and Asia branched chain amino acids
(BCAA) and L-ornithine L-aspartate (LOLA) respectively are pre-
ferred after lactulose. This could be due to the unavailability of
LOLA and BCAA in the US. On the other hand <1% from Europe
report probiotic use compared with 20% in the US and Asia, which
could reﬂect real-practice differences. Interestingly, while clinical
impression is used to assess treatment efﬁcacy in most respon-
dents, only 4% of US-based clinicians used blood ammonia levels
in contrast to their European and Asian counterparts.
Diagnosis and treatment of covert HE
Sixty percent of clinicians engage in some form of covert HE (CHE)
screening procedure. However, only 1/10 refer the majority of
patients for formal screening. Most clinicians focus screening
efforts on select patient sub-groups: prior overt HE, speciﬁc cog-
nitive complaints from caregiver or patient, and patients’ quality
of life (QoL) issues being the major reasons for screening referral.
As found by others, Portosystemic Encephalopathy Syndrome Test
(PSE) is the preferred psychometric test (41%) along with Critical
Flicker Frequency (CFF) (37%) [3]. As expected there are intercon-
tinental differences: PSE is Europe’s favoured test whereas the
Stroop EncephalApp and CFF are preferred in America and Asia,
respectively. Interestingly, systematic QoL assessment is widely
used (40%) indicating that the established close link between
CHE and QoL, albeit tempered by its relationship with cirrhosis
severity, is being strongly considered in clinical practice. Most
clinicians report that they initiate CHE treatment (with the same
drugs as in OHE) on a case-to-case basis but when asked to
recount cases that were started on CHE treatment in the last
month <5% of those fulﬁlling local CHE criteria were treated.
This could reﬂect the gap between knowledge, attitudes and the
ultimate translation into practice. The respondents felt that there
were still a wide range of unanswered questions regarding CHE
management. Importantly, the 40% who do not engage in CHE
screening are reluctant for several reasons: 43% ﬁnd screening too
time consuming and a similar proportion ﬁnds that lack of consen-
sus and trained personnel hinders screening efforts. These obstacles
seem to be most pronounced in America but have seemingly dimin-
ished since 2007 where a similar query was done [4].
HE and trafﬁc safety
Several studies have shown that HE patients may have difﬁculties
with driving and a convincing 99% agree that covert and recent
overt HE impact on driving skills. Respondents answered driv-
ing-related questions in accordance with their local driving regu-
lations. We found that only 1/5 of the respondents translated this
issue into practice and asked >60% of patients about driving his-
tory, often recommending driving restrictions. On the other
extreme a similar proportion ask <5% of patients. Most used clin-
ical impression to categorize patients as unsafe drivers, however
some also considered trafﬁc history (45%), psychometric test
results (40%), time since OHE (38%), and caregivers opinion
(37%) in making this judgement. Overall, 79% had at some point
urged patients with recent OHE (<3 months) and 67% with CHE
not to drive; but during the past month driving restrictions had
been recommended in very few patients. In case of any prior, cur-
rently controlled OHE even fewer would recommend driving
restrictions. This inconsistency between knowledge and practice
reﬂects the fact that 75% of respondents ﬁnd it difﬁcult to deal
with trafﬁc safety issues and only half are aware of local laws
which were also interpreted differently.
In this survey of clinical investigators interested in HE, 60% of
respondents offer screening for the presence of CHE via different
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